Malignant neoplasms of the eye, orbit, and adnexa (excluding skin)
The VA rates Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) under Diagnostic Code 6014 at a single 100% level. The applicable level depends on the full criteria and the evidence for the condition. These percentages are alternatives, not amounts to add together.
Rating schedule — DC 6014 at a glance
- Minimum rating
- 100%
- Maximum rating
- 100%
- Rating tiers
- 1
- CFR section
- § 4.79
- Body system
- Organs of Special Sense
- Secondary conditions
- 0
Lowest schedular rating available
Full schedular disability
100%
Part 4 rating schedule
None mapped
What are the VA rating criteria for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin)?
| Rating | Criteria |
|---|---|
| 100% | Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation |
“Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation”
What other organs of special sense conditions does the VA rate?
These diagnostic codes sit next to Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) in 38 CFR Part 4. The rating schedule is ordered anatomically, so neighbouring codes usually cover the same joint, organ, or system, and a claim often involves more than one of them.
- 6009Unhealed eye injuryRated up to 60%
- 6010Tuberculosis of eyeRated up to 100%
- 6011Retinal scars, atrophy, or irregularitiesRated up to 10%
- 6012Angle-closure glaucomaRated up to 10%
- 6013Open-angle glaucomaRated up to 10%
- 6016Nystagmus, centralRated up to 10%
- 6017Trachomatous conjunctivitisRated up to 30%
- 6018Chronic conjunctivitis (nontrachomatous)Rated up to 10%
- 6020EctropionRated up to 20%
- 6021EntropionRated up to 20%
Common Questions About Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) VA Ratings
What is the VA rating range for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin)?
The VA rates Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) under Diagnostic Code 6014 at 100%. The minimum 100% rating requires: Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation. The maximum 100% rating requires: Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation.
Which 38 CFR diagnostic code does the VA use for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin)?
The VA rates Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) under Diagnostic Code (DC) 6014, governed by 38 CFR 38 CFR § 4.79. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.
Can Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) qualify for TDIU?
Yes — a 100% rating for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) alone meets the single-disability threshold for TDIU (38 CFR § 4.16). If the condition prevents substantially gainful employment, the veteran is compensated at the 100% rate without a schedular 100% rating.
What evidence supports a higher rating for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin)?
The key evidence for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) is documentation of how the condition affects daily functioning. Treatment records showing worsening symptoms, functional limitations documented by your provider, and buddy statements describing observable impact on daily life all strengthen the claim. A nexus letter from a qualified medical professional linking the current severity to service is essential for contested claims.
What happens at the C&P exam for Malignant neoplasms of the eye, orbit, and adnexa (excluding skin)?
The C&P examiner uses a Organs of Special Sense DBQ and evaluates your condition against the DC 6014 rating criteria. The examiner documents symptom frequency, severity, and functional impact. Bring all treatment records and describe your worst days, not your best — the VA rates on the full clinical picture across time, not a snapshot of one good day.
Get a Personalized Rating Analysis
VeteranHQ evaluates your symptoms against the exact 38 CFR criteria, identifies secondary conditions, and shows what evidence you need to support a higher rating.
Discover Your Benefits